The Lynx Group

May 2014, Vol 5, No 4

San Diego, CA—Palbociclib, an inhibitor of cyclin-dependent kinase (CDK) 4/6, demonstrated “striking” activity when combined with conventional hormone therapy for patients with metastatic breast cancer, according to the results of an open-label phase 2 trial presented at the 2014 American Association for Cancer Research annual meeting.
Read Article

Los Angeles, CA—The Fourth Annual Conference of the Association for Value-Based Cancer Care, held May 6-9, 2014, kicked off 4 days of presentations by oncology stakeholders from across the country, including patients, physicians, pharmacists, nurses, payers, healthcare investors, and drug and diagnostics makers.
Read Article

Page 4 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: